This study randomized 1:1, 906 patients to receive zotarolimus-eluting stent and 905 patients to receive everolimus-eluting stent. The clinical and angiographic characteristics of both groups were similar with approximately 45% of the population experiencing an acute coronary syndrome. There were no significant differences in major cardiac events between the two stents with 6.1% to for zotarolimus and 5.1% for everolimus. There were no differences in the rate of stent thrombosis. Both stents showed safety and efficacy.
2_clemens_von_birgelen
Clemens von Birgelen
2013-10-31
Original title: DUTCH PEERS (TWENTE II): A Prospective, Randomized, “All-Comers” Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents
